Pacific Biosciences of California Inc (NASDAQ: PACB) on Friday, soared 6.16% from the previous trading day, before settling in for the closing price of $1.46. Within the past 52 weeks, PACB’s price has moved between $1.25 and $14.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 24.48% over the last five years. The company achieved an average annual earnings per share of 15.88%. With a float of $255.73 million, this company’s outstanding shares have now reached $267.74 million.
The firm has a total of 796 workers. Let’s measure their productivity.
Pacific Biosciences of California Inc (PACB) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Pacific Biosciences of California Inc is 6.08%, while institutional ownership is 101.19%. The most recent insider transaction that took place on Mar 06 ’24, was worth 176,160. In this transaction Director of this company bought 40,000 shares at a rate of $4.40, taking the stock ownership to the 40,000 shares. Before that another transaction happened on Mar 04 ’24, when Company’s insider sold 14,177 for $4.87, making the entire transaction worth $69,056. This insider now owns 2,596,670 shares in total.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Pacific Biosciences of California Inc (PACB) is currently performing well based on its current performance indicators. A quick ratio of 7.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.82 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Analysing the last 5-days average volume posted by the [Pacific Biosciences of California Inc, PACB], we can find that recorded value of 29.07 million was better than the volume posted last year of 9.84 million. As of the previous 9 days, the stock’s Stochastic %D was 8.98%. Additionally, its Average True Range was 0.37.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 3.19%, which indicates a significant decrease from 12.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 291.98% in the past 14 days, which was higher than the 137.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.2270, while its 200-day Moving Average is $8.0466. Now, the first resistance to watch is $1.6699. This is followed by the second major resistance level at $1.7898. The third major resistance level sits at $1.9096. If the price goes on to break the first support level at $1.4302, it is likely to go to the next support level at $1.3104. Should the price break the second support level, the third support level stands at $1.1905.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
Market capitalization of the company is 422.03 million based on 267,952K outstanding shares. Right now, sales total 200,520 K and income totals -306,740 K. The company made 58,360 K in profit during its latest quarter, and -82,020 K in sales during its previous quarter.
